Stock Analiz

cbdMD, Inc. YCBD

Package Goods/Cosmetics · IPO 2017 · data as of November 13, 2026

$0.37Market cap $5M
Open the interactive analysis →

cbdMD, Inc. (YCBD) is a consumer discretionary company listed in the US with a market value of about $5M. In the twelve months to June 30, 2026 it had revenue of $21M and net income of -$3M, a net margin of -13.8%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -14% a year, a 5-year average ROIC of -120%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 90% below the current price.

About cbdMD

cbdMD is listed in the US and classified in package goods/cosmetics, IPO year 2017. Revenue went from $2M in 2016 to $19M in 2025, growth of about 28.3% a year. It was profitable in 2 of the last 10 years in our data. Its share count rose by 2324% over three years (dilution for shareholders).

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Profit margin improving
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.2
P/B0.6
EV/EBITDA—
PEG—
Dividend yield—
FCF yield-47.9%
Shareholder yield0.0%
Intrinsic value vs. price−90%

Growth and quality

Revenue growth (1 yr)-1.5%
Revenue growth (5 yrs, per year)-14.4%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-75.0%
ROIC (5-yr avg.)-119.7%
Profitable years (of last 10)2
Years paying a dividend2

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$21M$19M$19M$24M$35M$44M$42M$24M$459091$4M$2M
Net income-$3M-$2M-$4M-$23M-$70M-$23M$13M-$51M$62834-$1M-$4M
Free cash flow-$2M-$2M-$542807-$5M-$16M-$14M-$12M-$17M-$6M-$2M-$3M
EPS (diluted)$0.24$-1.09$-14.29$-106.56$-446.40$-169.20$100.80$0.00$0.00$-136.80$-406.80
Net margin-13.8%-10.6%-19.0%-95.0%-198.0%-52.6%30.1%-217.1%13.7%-31.0%-191.8%
ROIC—-27.0%-160.8%-173.0%-220.3%-17.3%-17.9%-37.4%-12.8%-25.5%-264.6%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is cbdMD stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 90% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does cbdMD pay a dividend?

Not currently.

Is cbdMD a good stock to buy?

We do not give buy or sell advice. cbdMD scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.